Skip to main content

Table 6 Impact of various independent variables on achieving pCR

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Variable Univariate analysis Multivariate analysis
P value OR (95% CI) P value OR (95% CI)
Primary tumor size 0.083 1.032 (0.996–1.07) 0.241 01.031 (0.98–1.085)
High tumor grade (III) 0.049 3.75 (1.003–14.02) 0.025 0.015 (0.0–0.585)
HER2 positivity 0.007 0.171 (0.48–0.617) 0.02 0.055 (0.005–0.636)
Ki67 positivity 0.037 0.179 (0.035–0.903) 0.018 0.028 (0.001–0.548)
TILs 0.022 0.227 (0.064–0.80) 0.015 0.058 (0.006–0.58)
NACT (Carboplatin+Gemcitabine) 0.853 0.895 (0.275–2.91) 0.518 1.94 (0.26–14.46)
Molecular subtype
 HR+/HER2+ 0.005 0.045 (0.005–0.399) 0.026 0.048 (0.003–0.69)
 HR−/HER2+ 0.218 0.149 (0.007–3.078) 0.368 0.158 (0.003–8.831)
 HR−/HER2- 0.036 0.050 (0.003–0.824) 0.452 0.244 (0.006–9.628)
  1. NACT Neoadjuvant chemotherapy, TIL Tumor-infiltrating lymphocytes, HR Hormone receptor, OR Odd Ratio, CI Confidence Interval